McDonald's hit with lawsuit claiming McRib contains no real rib meat

Four plaintiffs filed a class-action suit in U.S. District Court for the Northern District of Illinois alleging the McRib contains no actual pork rib meat and is made from ground pork shoulder and other lower-grade parts (allegedly including heart, tripe and scalded stomach). McDonald's called the claims meritless, stating the McRib is made from "100% seasoned boneless pork" sourced in the U.S., and noted transparency on ingredients; the sandwich returned to many menus in November as a limited-time item. The suit raises reputational and potential liability risks for McDonald's (MCD $299.86, -1.12% as shown), but at this stage the company’s denial and product popularity suggest limited near-term financial impact absent escalation or regulatory action.

Analysis

Market structure: This lawsuit is a reputational/marketing event with limited direct supply-chain implications—McDonald’s (MCD) derives <5% of annual revenue from limited-time SKUs like the McRib, so revenue shock is likely under 1–2% assuming a prolonged 6–12 month hit to returns. Winners are competing QSRs (YUM, SBUX) and private-label pork processors only if consumer substitution occurs; losers are headline-sensitive MCD short-term holders and social-media-driven retail flows. Pricing power for MCD’s core business is unlikely to shift materially unless litigation produces large fines or forced labeling changes (>USD 50–100m).

Risk assessment: Tail risks include a successful class certification plus a large statutory damages judgment or FTC/USDA labeling action—low probability but material (>$100m liability, reputational loss >1–3% same-store-sales for a quarter). Time horizons: immediate (days) = headline-driven IV spikes; short-term (weeks–months) = PR/marketing spend and potential sales dip; long-term (quarters–years) = negligible unless systematic supply issues or regulatory precedent emerges. Hidden dependency: viral social sentiment can amplify retail flows and options gamma; catalyst list: class certification hearings (30–90 days), supplier disclosures, and any USDA/FTC inquiries.

Trade implications: Tactical approach favors defined-risk protection on MCD rather than outright large shorts. Buy 30–90 day put spreads to hedge headline risk while preparing to scale into long positions on >5–7% share-price weakness; consider going long YUM or SBUX vs. MCD if share weakness persists to capture relative flow rotation. Options: expect 15–30% IV repricing on MCD near-term—use debit put spreads or long-dated calls on dips for asymmetric payoff.

Contrarian angle: The market often overreacts to food labeling suits; historical parallels (class actions vs. large food brands) usually settle for low seven-figure amounts and don’t change fundamentals. If MCD falls >5% and no regulatory action within 60 days, the sell-off offers a buying opportunity—mean reversion probable given MCD’s 30%+ operating margin and $40bn+ market cap. Monitor legal calendar and same-store-sales prints for true signal.

Key Decisions for Investors

• Establish a 0.5% portfolio-sized hedged position: buy a 45–90 day MCD 300–285 put debit spread (defined max loss = premium) to protect against a >5% downside from current ~300 price over the next 1–3 months.
• If MCD trades down >5% intraday or >7% within 30 days with no regulatory escalation, deploy 1–2% portfolio buy of MCD shares (target weight 1–2%) with a 3–6 month horizon; set stop-loss at -12% and target exit at +8–12% or recovery to ~$325.
• Enter a relative-value pair: long YUM (YUM) 1% portfolio vs short MCD 1% (equal notional) if MCD underperforms peers by >200bp over a rolling 30-day period; hold 1–3 months to capture rotational flows.
• Avoid naked-option selling on MCD; if selling premium, use covered calls with strike >=+8% from purchase and max 3-month tenor. Monitor class-certification filings, any USDA/FTC notices, and MCD same-store sales weekly for 30–90 days—escalate or unwind positions if formal regulatory action or >$50m disclosure emerges.